Related Experiment Video

Updated: Jun 18, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology

Francesco Bertolini1

  • 1Laboratory of Hematology-Oncology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. francesco.bertolini@ieo.it

Breast (Edinburgh, Scotland)
|November 17, 2009
PubMed
Abstract

Insights

Identifying optimal anti-angiogenic drugs and dosages is challenging. Research into predictive biomarkers like circulating endothelial cells (CECs) and progenitors (CEPs) shows promise for improving cancer treatment. Further validation is needed.

Area of Science:

  • Oncology
  • Biomarker Discovery

Background:

  • Anti-angiogenic drugs are increasingly used in cancer therapy, but selecting the right drug, dose, and schedule remains difficult.
  • Predicting patient response to these therapies is a significant clinical challenge.

Purpose of the Study:

  • To review current surrogate biomarkers for angiogenesis and anti-angiogenic drug activity.
  • To highlight the complexities and needs in biomarker research for personalized cancer treatment.

Main Methods:

  • Literature review of existing data on angiogenesis biomarkers.
  • Analysis of circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) as predictive markers.

Main Results:

  • Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) show predictive potential in advanced breast cancer trials.
  • Molecular surrogate markers are currently limited due to difficulties in identifying endothelial-cell-specific targets.

Conclusions:

  • Validating new biomarkers for angiogenesis and anti-angiogenic drug activity is complex, involving biological, technical, and clinical factors.
  • Careful planning and validation in future clinical studies are essential for advancing personalized cancer therapy.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.